Liver Involvement in POLG Disease—a Multicentre Cohort Study of 202 Patients

Authors:
Publisher website
Google Scholar
Abstract
Liver involvement in POLG disease is common and associated with high morbidity and mortality. Detailed, large‐scale, systematic studies of liver involvement are lacking. This study aims to describe the onset, clinical course and prognostic implications of liver involvement in POLG disease. We conducted a multinational, retrospective study including clinical, genetic and biochemical data from patients with confirmed POLG disease. Patients were stratified according to age of disease onset: early‐onset (< 12 years), juvenile/adult‐onset (12–40 years), and late‐onset (> 40 years). Of the 202 patients, 110 (54%) had liver involvement. This could present at any time during the lifespan, but occurred more frequently in patients with early‐onset disease (76/98, 78%). Median onset age for liver involvement in females was 7 years (range: 1 month to 50 years), and 21 months in males (birth to 71 years). Infection‐triggered disease onset carried a significantly higher risk of liver involvement than spontaneous or other disease triggers. Eighty‐five percent of those with liver involvement also had epilepsy. Liver involvement was an indicator of poor prognosis and was significantly associated with worse survival. This study provides a comprehensive description of liver involvement in a large cohort of POLG disease patients. Liver involvement is common in this disease and associated with significantly worse survival. POLG disease should be considered in children presenting with liver involvement, and rapid genetic testing may guide management decisions. Our findings emphasize the need for early vigilance in monitoring liver involvement in all patients with confirmed POLG disease, particularly those with early‐onset disease and during intercurrent infection.
Funding Information
  • Helse Vest (911944)
  • Oslo universitetssykehus HF
  • Great Ormond Street Hospital Charity
  • Lily Foundation
  • National Institute for Health and Care Research
  • Medical Research Council (MR/V009346/1)
  • UK Research and Innovation (101120256)
  • UK Research and Innovation (MMM)
  • NIHR Cambridge Biomedical Research Centre (NIHR203312)
  • Ataxia UK
  • Action for A-T
  • Muscular Dystrophy UK
  • Rosetrees Trust (PGL23/100048)

This publication has 44 references indexed in Scilit: